A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Clinical trial NCT03311854 · COMPLETED
Trial details
- NCT number
- NCT03311854
- Sponsor
- Swedish Orphan Biovitrum
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-20
- Primary completion
- 2020-05-19
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.